Genmab Relies On Pipeline As J&J Opts Out Of Next-Gen Darzalex

Epkinly, Rina-S, Acasunlimab To Deliver Revenue Growth

 
• By Mandy Jackson
  
With or without a GEN3014 deal, Genmab is seeking growth through late-stage dealmaking (Shutterstock)

More from Deals

More from Scrip